المؤلفون: Baraibar Argota, Iosune, Garcia Rodriguez, Ariadna, Salva Ballabrera, Francesc, Ros Montañá, Fco. Javier, Castillo Cicuendez, Gloria, Sanchis Marin, Mireia, Garcia Alvarez, Alejandro, Hernando Cubero, Jorge, Rodríguez Castells, Marta, Martí Gallostra, Marc, Espín Basany, Eloy, Navalpotro Yagüe, Begoña, Guevara Cubas, Jorge Alonso, Dopazo Taboada, Cristina, Nuciforo, Paolo Giovanni, Vivancos Prellezo, Ana, Tabernero Caturla, Josep, Elez Fernandez, Mª Elena, Capdevila Castillon, Jaume, Landolfi, Stefania, Saoudi Gonzalez, Nadia, Comas Navarro, Raquel

المساهمون: Institut Català de la Salut, Baraibar I, Salvà F, Ros J, Saoudi N, García-Álvarez A, Hernando J, Capdevila J, Castells MR, Tabernero J, Élez E Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. García A, Comas R, Castillo G, Sanchis M Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Martí M, Espín E, Dopazo C Servei de Cirurgia General i Digestiva, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Landolfi S Servei d’Anatomia Patològica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Navalpotro B Servei d’Oncologia Radioteràpica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Guevara J Servei d’Aparell Digestiu, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Nuciforo P, Vivancos A Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Còlon - Càncer - Diagnòstic, Càncer - Detecció precoç, Recte - Càncer - Diagnòstic, COVID-19 (Malaltia), DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Early Diagnosis::Early Detection of Cancer, DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::diagnóstico precoz::detección precoz del cáncer, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales

الوصف: COVID-19 pandemic; Early-onset colorectal cancer ; Pandemia de COVID-19 Cáncer colorrectal precoz ; Pandèmia de COVID-19; Càncer colorectal precoç ; The COVID19 pandemic has affected the spectrum of cancer care worldwide. Early onset colorectal cancer (EOCRC) is defined as diagnosis below the age of 50. Patients with EOCRC faced multiple challenges during the COVID19 pandemic and in some institutions it jeopardized cancer diagnosis and care delivery. Our study aims to identify the clinicopathological features and outcomes of patients with EOCRC in our Centre during the first wave of the pandemic in comparison with the same period in 2019 and 2021. Patients with EOCRC visited for the first time at Vall d'Hebron University Hospital in Spain from the 1st March to 31st August of 2019, 2020 and 2021 were included in the analysis. 177 patients with EOCRC were visited for the first time between 2019 and 2021, of which 90 patients met the inclusion criteria (2019: 30 patients, 2020: 29 patients, 2021: 31 patients). Neither differences in frequency nor in stage at diagnosis or at first visit during the given periods were observed. Of note, indication of systemic therapy in the adjuvant or metastatic setting was not altered. Days to treatment initiation and enrollment in clinical trials in this subpopulation was not affected due to the COVID-19 outbreak. ; This work was supported by the Cancer Research UK (CRUK) grant OPTIMISTICC (C10674/A27140).

وصف الملف: application/pdf

العلاقة: Translational Oncology;32; https://doi.org/10.1016/j.tranon.2023.101668Test; Baraibar I, García A, Salvà F, Ros J, Saoudi N, Comas R, et al. Impact of the COVID-19 pandemic in the early-onset colorectal cancer. Transl Oncol. 2023 Jun;32:101668.; https://hdl.handle.net/11351/9430Test; 000866211600326

الإتاحة: https://doi.org/10.1016/j.tranon.2023.101668Test
https://hdl.handle.net/11351/9430Test

المؤلفون: Mitjavila Casanovas, Mercedes, Jimenez Fonseca, Paula, BELLO, PILAR, Pubul Núñez, Virginia, Percovich, Juan Carlos, Garcia-Burillo, Amparo, Hernando Cubero, Jorge

المساهمون: Institut Català de la Salut, Mitjavila M Department of Nuclear Medicine, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. Jimenez-Fonseca P Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain. Belló P Department of Nuclear Medicine, Hospital Universitario La Fe, Valencia, Spain. Pubul V Department of Nuclear Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain. Percovich JC Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Marañón, Madrid, Spain. Garcia-Burillo A Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hernando J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Tumors neuroendocrins - Tractament, Radiofàrmacs, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors, Other subheadings::Other subheadings::/therapy, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Diagnostic Uses of Chemicals::Radiopharmaceuticals, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos, Otros calificadores::Otros calificadores::/terapia, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos diagnósticos de sustancias químicas::radiofármacos

الوصف: Neuroendocrine tumor; Radionuclide therapy ; Tumor neuroendocrí; Teràpia amb radionúclids ; Tumor neuroendocrino; Terapia con radionúclidos ; Background Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy and safety of [177Lu]Lu-DOTATATE in NENs with different locations and evaluate the effect of the tumor origin, bearing in mind other prognostic variables. Advanced NENs overexpressing somatostatin receptors (SSTRs) on functional imaging, of any grade or location, treated at 24 centers were enrolled. The protocol consisted of four cycles of 177Lu-DOTATATE 7.4 GBq iv every 8 weeks (NCT04949282). Results The sample comprised 522 subjects with pancreatic (35%), midgut (28%), bronchopulmonary (11%), pheochromocytoma/ paraganglioma (PPGL) (6%), other gastroenteropancreatic (GEP) (11%), and other non-gastroenteropancreatic (NGEP) (9%) NENs. The best RECIST 1.1 responses were complete response, 0.7%; partial response, 33.2%; stable disease, 52.1%; and tumor progression, 14%, with activity conditioned by the tumor subtype, but with benefit in all strata. Median progression-free survival (PFS) was 31.3 months (95% CI, 25.7–not reached [NR]) in midgut, 30.6 months (14.4-NR) in PPGL, 24.3 months (18.0-NR) in other GEP, 20.5 months (11.8-NR) in other NGEP, 19.8 months (16.8–28.1) in pancreatic, and 17.6 months (14.4–33.1) in bronchopulmonary NENs. [177Lu]Lu-DOTATATE exhibited scant severe toxicity. Conclusion This study confirms the efficacy and safety of [177Lu]Lu-DOTATATE in a wide range of SSTR-expressing NENs, regardless of location, with clinical benefit and superimposable survival outcomes between pNENs and other GEP and NGEP tumor subtypes different from midgut NENs. ; The SEPTRALU registry received external funding from Novartis.

وصف الملف: application/pdf

العلاقة: European Journal of Nuclear Medicine and Molecular Imaging;50; https://doi.org/10.1007/s00259-023-06166-8Test; Mitjavila M, Jimenez-Fonseca P, Belló P, Pubul V, Percovich JC, Garcia-Burillo A, et al. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging. 2023 Jul;50:2486–500.; https://hdl.handle.net/11351/9825Test; 000951227100001

الإتاحة: https://doi.org/10.1007/s00259-023-06166-8Test
https://hdl.handle.net/11351/9825Test

المؤلفون: Hernando Cubero, Jorge, Teule, Alex, Lopez, C., Garcia-Carbonero, Rocio, Benavent, Marta, Landolfi, Stefania, Capdevila Castillon, Jaume, Nuciforo, Paolo

المساهمون: Institut Català de la Salut, Capdevila J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medical Oncology Department, IOB-Quiron-Teknon, Barcelona, Spain. Hernando J Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Teule A Medical Oncology Department, Institut Català d’Oncologia (ICO) - IDIBELL L’Hospitalet del Llobregat, L’Hospitalet de Llobregat, Spain. Lopez C Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. Garcia-Carbonero R Medical Oncology Department, Hospital Universitario 12 de Octubre, Imas12, UCM, CNIO, Madrid, Spain. Benavent M Medical Oncology Department, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain. Landolfi S Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERONC, Barcelona, Spain. Nuciforo P Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Anticossos monoclonals - Ús terapèutic, Tumors neuroendocrins - Tractament, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal, Other subheadings::Other subheadings::Other subheadings::/drug therapy, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos

الوصف: Cancer immunotherapy; Neuroendocrine cancer; Tumour immunology ; Immunoteràpia del càncer; Càncer neuroendocrí; Immunologia tumoral ; Inmunoterapia del cáncer; Cáncer neuroendocrino; Inmunología tumoral ; Single immune checkpoint blockade in advanced neuroendocrine neoplasms (NENs) shows limited efficacy; dual checkpoint blockade may improve treatment activity. Dune (NCT03095274) is a non-randomized controlled multicohort phase II clinical trial evaluating durvalumab plus tremelimumab activity and safety in advanced NENs. This study included 123 patients presenting between 2017 and 2019 with typical/atypical lung carcinoids (Cohort 1), G1/2 gastrointestinal (Cohort 2), G1/2 pancreatic (Cohort 3) and G3 gastroenteropancreatic (GEP) (Cohort 4) NENs; who progressed to standard therapies. Patients received 1500 mg durvalumab and 75 mg tremelimumab for up to 13 and 4 cycles (every 4 weeks), respectively. The primary objective was the 9-month clinical benefit rate (CBR) for cohorts 1-3 and 9-month overall survival (OS) rate for Cohort 4. Secondary endpoints included objective response rate, duration of response, progression-free survival according to irRECIST, overall survival, and safety. Correlation of PD-L1 expression with efficacy was exploratory. The 9-month CBR was 25.9%/35.5%/25% for Cohorts 1, 2, and 3 respectively. The 9-month OS rate for Cohort 4 was 36.1%, surpassing the futility threshold. Benefit in Cohort 4 was observed regardless of differentiation and Ki67 levels. PD-L1 combined scores did not correlate with treatment activity. Safety profile was consistent with that of prior studies. In conclusion, durvalumab plus tremelimumab is safe in NENs and shows modest survival benefit in G3 GEP-NENs; with one-third of these patients experiencing a prolonged OS. ; This work was supported by the Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE). AstraZeneca provided durvalumab and tremelimumab and awarded a grant to GETNE to pay the costs of the study. The funder did not have a role in designing or ...

وصف الملف: application/pdf

العلاقة: Nature Communications;14; https://doi.org/10.1038/s41467-023-38611-5Test; Capdevila J, Hernando J, Teule A, Lopez C, Garcia-Carbonero R, Benavent M, et al. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. Nat Commun. 2023 May 23;14:2973.; https://hdl.handle.net/11351/9654Test

الإتاحة: https://doi.org/10.1038/s41467-023-38611-5Test
https://hdl.handle.net/11351/9654Test

المؤلفون: Aparicio Urtasun, Jorge, Virgili Manrique, Anna Cristina, Capdevila, J., Muñoz Boza, F., Galván, Patricia, Richart, P., Oliveres, H., Páez, David, Hernando Cubero, Jorge, Serrano, S., Vera, R., Hernandez-Yagüe, X., Gallego, R.Ã., Riesco-Martinez, M.C., García de Albeniz, X., Maurel, Joan

مصطلحات موضوعية: Colorectal cancer, Metastatic disease, Second line therapy, Panitumumab, Liquid biopsy

الوصف: Altres ajuts: Fundació la Marató de TV3 (201330.10); Fundacion Olga Torres (Modalitat A. 2019/2020); Spanish Association Against Cancer (AECC, PROYE19040POST_001). ; Purpose: Panitumumab plus FOLFOX (P-FOLFOX) is standard first-line treatment for RAS wild-type (WT) metastatic colorectal cancer. The value of panitumumab rechallenge is currently unknown. We assessed addition of panitumumab to FOLFIRI (P-FOLFIRI) beyond progression to P-FOLFOX in patients with no RAS mutations in liquid biopsy (LB). Methods: In this randomized phase II trial, patients were assigned (3:2 ratio) to second-line P-FOLFIRI (arm A) or FOLFIRI alone (arm B). LB for circulating tumor DNA analysis was collected at study entry and at disease progression. Primary endpoint was 6-month progression-free survival. Two-stage Simon design required 85 patients to be included (EudraCT 2017-004519-38). Results: Between February 2019 and November 2020, 49 patients were screened (16 RAS mutations in LB detected) and 31 included (18 assigned to arm A and 13 to arm B). The study was prematurely closed due to inadequate recruitment. Serious adverse events were more frequent in arm A (44% vs. 23%). Overall response rate was 33% (arm A) vs. 7.7% (arm B). Six-month progression-free survival rate was 66.7% (arm A) and 38.5% (arm B). Median progression-free survival was 11.0 months (arm A) and 4.0 months (arm B) (hazard ratio, 0.58). At disease progression, RAS or BRAF mutations in LB were found in 4/11 patients (36%) in arm A and 2/10 (20%) in arm B. Conclusions: The BEYOND study suggests a meaningful benefit of P-FOLFIRI beyond progression to P-FOLFOX in metastatic colorectal cancer patients with WT RAS status selected by LB. This strategy deserves further investigation.

وصف الملف: application/pdf

العلاقة: Agència de Gestió d'Ajuts Universitaris i de Recerca 2014-SGR-474; Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-1174; Instituto de Salud Carlos III PI13/01728; Instituto de Salud Carlos III PI19/00740; Clinical & Translational Oncology; Vol. 24 Núm. 11 (november 2022), p. 2155-2165; https://ddd.uab.cat/record/275177Test; urn:10.1007/s12094-022-02868-x; urn:oai:ddd.uab.cat:275177; urn:scopus_id:85132869470; urn:articleid:16993055v24n11p2155; urn:pmid:35761123; urn:pmc-uid:9522782; urn:pmcid:PMC9522782; urn:oai:pubmedcentral.nih.gov:9522782

الإتاحة: https://ddd.uab.cat/record/275177Test

المؤلفون: Garcia Alvarez, Alejandro, Hernando Cubero, Jorge, Carmona Alonso, Ana, Capdevila Castillon, Jaume

المساهمون: Institut Català de la Salut, Garcia-Alvarez A, Hernando J, Carmona-Alonso A, Capdevila J Unitat de Tumors Gastrointestinals i Endocrins, Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Tiroide - Càncer - Tractament, Immunoteràpia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms, Other subheadings::Other subheadings::Other subheadings::/drug therapy, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia

الوصف: Immunotherapy; Thyroid neoplasms; Tumor mutational burden ; Inmunoterapia; Neoplasias de la tiroides; Carga mutacional tumoral ; Immunoteràpia; Neoplàsies de les tiroides; Càrrega mutacional tumoral ; Immunotherapy has changed the treatment of patients with advanced cancer, with different phase III trials showing durable responses across different histologies. This review focuses on the preclinical and clinical evidence of potential predictive biomarkers of response and efficacy of immunotherapy in thyroid neoplasms. Programmed death-ligand 1 (PD-L1) staining by immunohistochemistry has shown higher expression in anaplastic thyroid cancer (ATC) compared to other subtypes. The tumor mutational burden in thyroid neoplasms is low but seems to be higher in ATC. Immune infiltrates in the tumor microenvironment (TME) differ between the different thyroid neoplasm subtypes. In general, differentiated thyroid cancer (DTC) has a higher number of tumor-associated lymphocytes and regulatory T cells (Tregs), while ATC and medullary thyroid cancer (MTC) display a high density of tumor-associated macrophages (TAMs). Nevertheless, results from clinical trials with immunotherapy as monotherapy or combinations have shown limited efficacy. Further investigation into new strategies aside from anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4)/programmed death 1 (PD-1)/PD-L1 antibodies, validation of predictive biomarkers, and better population selection for clinical trials in thyroid neoplasms is more than needed in the near future.

وصف الملف: application/pdf

العلاقة: Frontiers in Endocrinology;13; https://doi.org/10.3389/fendo.2022.929091Test; Garcia-Alvarez A, Hernando J, Carmona-Alonso A, Capdevila J. What is the status of immunotherapy in thyroid neoplasms? Front Endocrinol. 2022 Aug 5;13:929091.; https://hdl.handle.net/11351/8342Test; 000842917900001

الإتاحة: https://doi.org/10.3389/fendo.2022.929091Test
https://hdl.handle.net/11351/8342Test

المؤلفون: Muñoz de Nova, Jose Luis, Hernando Cubero, Jorge, Sampedro-Núñez, Miguel, Vázquez Benítez, Greissy Tibisay, Triviño-Ibañez, Eva-Maria, Del Olmo García, Maria Isabel, Barriuso, J., Martin-Perez, Elena, Capdevila Castillon, Jaume

المساهمون: Institut Català de la Salut, Muñoz de Nova JL, Martín-Pérez E Department of General and Digestive Surgery, Hospital Universitario de La Princesa, Madrid 28006, Spain. Department of Surgery, Universidad Autónoma de Madrid, Madrid 28029, Spain. Hernando J, Capdevila J Tumors Gastrointestinals i Endocrins, Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Sampedro Núñez M Department of Endocrinology and Nutrition, Hospital Universitario de La Princesa, Madrid 28006, Spain. Vázquez Benítez GT Department of Pathology, Hospital Universitario Puerta de Hierro, Madrid 28222, Spain. Department of Pathology, Universidad Autónoma de Madrid, Madrid 28029, Spain. Triviño Ibáñez EM Department of Nuclear Medicine, Virgen de las Nieves University Hospital, Granada 18014, Spain. Del Olmo García MI Department of Endocrinology and Nutrition, Hospital Universitario i Politècnic La Fe, Valencia 46023, Spain. Barriuso J Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, United Kingdom. Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Apendicectomia, Tumors neuroendocrins - Diagnòstic, Apèndix (Anatomia) - Càncer, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors, Other subheadings::Other subheadings::/diagnosis, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Digestive System Surgical Procedures::Appendectomy, DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Cecal Neoplasms::Appendiceal Neoplasms, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos, Otros calificadores::Otros calificadores::/diagnóstico, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::procedimientos quirúrgicos del sistema digestivo::apendicectomía, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias del ciego::neoplasias del apéndice

الوصف: Appendiceal neoplasms; Carcinoid tumor; Treatment outcome ; Neoplasias apendiculares; Tumor carcinoide; Resultado del tratamiento ; Neoplàsies apendiculars; Tumor carcinoide; Resultat del tractament ; Appendiceal neuroendocrine tumors (aNETs) are an uncommon neoplasm that is relatively indolent in most cases. They are typically diagnosed in younger patients than other neuroendocrine tumors and are often an incidental finding after an appendectomy. Although there are numerous clinical practice guidelines on management of aNETs, there is continues to be a dearth of evidence on optimal treatment. Management of these tumors is stratified according to risk of locoregional and distant metastasis. However, there is a lack of consensus regarding tumors that measure 1-2 cm. In these cases, some histopathological features such as size, tumor grade, presence of lymphovascular invasion, or mesoappendix infiltration must also be considered. Computed tomography or magnetic resonance imaging scans are recommended for evaluating the presence of additional disease, except in the case of tumors smaller than 1 cm without additional risk factors. Somatostatin receptor scintigraphy or positron emission tomography with computed tomography should be considered in cases with suspected residual or distant disease. The main point of controversy is the indication for performing a completion right hemicolectomy after an initial appendectomy, based on the risk of lymph node metastases. The main factor considered is tumor size and 2 cm is the most common threshold for indicating a colectomy. Other factors such as mesoappendix infiltration, lymphovascular invasion, or tumor grade may also be considered. On the other hand, potential complications, and decreased quality of life after a hemicolectomy as well as the lack of evidence on benefits in terms of survival must be taken into consideration. In this review, we present data regarding the current indications, outcomes, and benefits of a colectomy.

وصف الملف: application/pdf

العلاقة: World journal of gastroenterology;28(13); http://dx.doi.org/10.3748/wjg.v28.i13.1304Test; Muñoz de Nova JL, Hernando J, Sampedro Núñez M, Vázquez Benítez GT, Triviño Ibáñez EM, Del Olmo García MI, et al. Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy. World J Gastroenterol. 2022 Apr 7;28(13):1304–14.; https://hdl.handle.net/11351/8075Test; 000797337500002

الإتاحة: https://doi.org/10.3748/wjg.v28.i13.1304Test
https://hdl.handle.net/11351/8075Test

المؤلفون: Cives, Mauro, Hernando Cubero, Jorge, Lamarca, Angela, Bouvier, Catherine, Caplin, Martyn, Pavel, Marianne E.

المساهمون: Institut Català de la Salut, Cives M Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”, Bari, Italy. Hernando J Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Lamarca A Department of Medical Oncology, The Christie NHS Foundation, Manchester, Division of Cancer Sciences, University of Manchester, Manchester, UK. Bouvier C International Neuroendocrine Cancer Alliance (INCA), Boston, Massachusetts, USA. Caplin M Neuroendocrine Tumor Unit, Royal Free Hospital, London, UK. Pavel M Department of Medicine 1, Endocrinology, Friedrich Alexander Universität ErlangenNürnberg, Erlangen, Germany, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Telemedicina, Tumors neuroendocrins - Tractament, COVID-19 (Malaltia), DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors, Other subheadings::Other subheadings::/therapy, HEALTH CARE::Health Services Administration::Patient Care Management::Delivery of Health Care::Telemedicine, DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos, Otros calificadores::Otros calificadores::/terapia, ATENCIÓN DE SALUD::administración de los servicios de salud::gestión de la atención al paciente::prestación sanitaria::telemedicina, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus

الوصف: SARS-CoV-2; Carcinoids; Vaccination ; SARS-CoV-2; Carcinoides; Vacunación ; SARS-CoV-2; Carcinoides; Vacunació ; The COVID-19 outbreak has added complexity in the management of patients with neuroendocrine tumors (NETs). Little information is currently available regarding the real impact of the pandemic in current practice. The present study aimed to capture patients' and healthcare professionals' experiences on how the NET management has changed during the pandemic and how it should be modified in a foreseeable post-pandemic environment. Physicians and nurses working in ENETS Centers of Excellence or other hospitals with high volume of NET patients (n = 48), as well as NET patients residing worldwide (n = 353), were asked to respond to two online anonymous surveys addressing different aspects of NET care. Deferred diagnoses, delayed surveillance procedures and postponed elective surgeries were among the main negative consequences of the COVID-19 outbreak according to 40%, 54% and 46% of healthcare professionals (HPs) respectively. Somatostatin analogs were increasingly used as bridging strategy for delaying surgery based on the views of 31% of HPs and were self-injected or delivered by home care services more frequently than before the initiation of the pandemic (53% of patients during the pandemic vs. 44% before the pandemic). Multidisciplinary tumor boards kept their usual schedule according to 58% of HPs, but were held virtually in the 77% of cases. The contact with healthcare professionals was maintained by remote methods more often than in the past (69% of patients), but only 34% of patients (59% among subjects < 41 years) would prefer telemedicine to face-to-face consultations in the future. New health policy measures should guarantee the highest standard of treatment to NET patients, regardless of the trajectory followed by the COVID-19 pandemic in the next months. Pros and cons of telemedicine should be carefully weighted before systematic implementation. ; We thank INCA and its members for ...

وصف الملف: application/pdf

العلاقة: Journal of Neuroendocrinology;34(10); https://doi.org/10.1111/jne.13196Test; Cives M, Hernando J, Lamarca A, Bouvier C, Caplin M, Pavel M, et al. The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients. J Neuroendocrinol. 2022 Oct;34(10):e13196.; https://hdl.handle.net/11351/8401Test; 000850714900001

الإتاحة: https://doi.org/10.1111/jne.13196Test
https://hdl.handle.net/11351/8401Test

المؤلفون: Mirallas Viñas, Oriol, Filippi Arriaga, Maria Francesca Eugenia, Hernández Hernández, Irene, Aubanell, Anton, Chaachou, Anas, Garcia-Alvarez, Alejandro, Hernando Cubero, Jorge, Martinez Saez, Elena Antima, Biagetti Biagetti, Betina, Capdevila Castillon, Jaume

المساهمون: Institut Català de la Salut, Mirallas O, Garcia-Alvarez A, Hernando J, Capdevila J Servei d’Oncologia Mèdica, Unitat de Tumors Gastrointestinals i Endocrins, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Filippi-Arriaga F Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hernandez Hernandez I, Biagetti B Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Aubanell A Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Chaachou A, Martínez-Saez E Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Adenoma - Tractament, Hipòfisi - Tumors - Tractament, Quimioteràpia combinada, DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Pituitary Neoplasms::ACTH-Secreting Pituitary Adenoma::Nelson Syndrome, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Adenoma, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias hipofisarias::adenoma hipofisario secretor de ACTH::síndrome de Nelson, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::adenoma

الوصف: Agressive pituitary tumors; Capecitabine; Temozolomide ; Tumores hipofisarios agresivos; Capecitabina; Temozolomida ; Tumors hipofisaris agressius; Capecitabina; Temozolomida ; Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.

وصف الملف: application/pdf

العلاقة: Frontiers in Endocrinology;12; https://doi.org/10.3389/fendo.2021.731631Test; Mirallas O, Filippi-Arriaga F, Hernandez Hernandez I, Aubanell A, Chaachou A, Garcia-Alvarez A, et al. Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report. Front Endocrinol. 2021 Nov 11;12:731631.; https://hdl.handle.net/11351/7615Test; 000727887300001

الإتاحة: https://doi.org/10.3389/fendo.2021.731631Test
https://hdl.handle.net/11351/7615Test

المؤلفون: Hernando Cubero, Jorge, Alonso, Lola, Fasani, Roberta, Jiménez Flores, José Antonio, Elez Fernandez, Mª Elena, Tabernero Caturla, Josep, Nuciforo, Paolo Giovanni, Capdevila Castillon, Jaume, Landolfi, Stefania, Comas Navarro, Raquel, Ruiz Pace, Fiorella, Serna, Garazi, Dienstmann, Rodrigo

المساهمون: Institut Català de la Salut, Serna G, Alonso L, Fasani R, Jimenez J, Nuciforo P Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Ruiz-Pace F, Comas R, Dienstmann R Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Hernando J, Elez E, Capdevila J Servei d’Oncologia Mèdica, Unitat de Tumors gastrointestinals i endocrins, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. Landolfi S Servei d’Anatomia Patològica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Tabernero J Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Bacteris gramnegatius, Recte - Càncer - Quimioteràpia, Recte - Càncer - Radioteràpia, DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms::Rectal Neoplasms, ORGANISMS::Bacteria::Bacteria::Gram-Negative Bacteria::Gram-Negative Anaerobic Bacteria::Gram-Negative Anaerobic Straight, Curved, and Helical Rods::Fusobacterium::Fusobacterium nucleatum, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Chemoradiotherapy, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales::neoplasias del recto, ORGANISMOS::Bacteria::Bacteria::bacterias gramnegativas::bacterias anaerobias gramnegativas::bacilos anaerobios gramnegativos, rectos, curvos y espirales::Fusobacterium::Fusobacterium nucleatum, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::quimiorradioterapia

الوصف: Fusobacterium nucleatum; Càncer de recte avançat local; Quimioteràpia preoperatòria ; Fusobacterium nucleatum; Cáncer de recto avanzado local; Quimiorradioterapia preoperatoria ; Fusobacterium nucleatum; Locally advanced rectal cancer; Preoperative chemoradiotherapy ; Background Accumulating evidence has identified Fusobacterium as an important pathogenic gut bacterium associated with colorectal cancer. Nevertheless, only limited data exist about the role of this bacterium in locally advanced rectal cancer (LARC). In this study, we quantified Fusobacterium nucleatum in untreated and post-neoadjuvant chemoradiotherapy (nCRT) samples from LARC patients and investigated its association with therapy response and survival. Patients and methods A total of 254 samples from 143 patients with rectal adenocarcinomas were analyzed for the presence and abundance of F. nucleatum using RNA in situ hybridization and digital image analysis. Assay accuracy was determined using infected cell lines and tumor samples with available quantitative PCR data. We studied the impact of F. nucleatum load on pathologic complete response and relapse-free survival. Treatment-induced changes were evaluated in paired pre- and post-nCRT samples (n = 71). Finally, tumor microenvironment changes during nCRT were assessed in paired samples (n = 45) by immune contexture analysis. Results F. nucleatum tissue levels by RNA in situ hybridization strongly correlated with quantitative PCR (r = 0.804, P < 0.001). F. nucleatum abundance was higher in untreated [median, 7.4; 95% confidence interval (3.7–16.2)] compared with treated [median, 1.6; 95% confidence interval (1.3–2.4)] tumors (P <0.001) with 58% (73/126) and 26% (22/85) positive tumors, respectively (P < 0.001). Baseline F. nucleatum levels were not associated with pathologic complete response. F. nucleatum positivity after nCRT, but not baseline status, significantly increased risk of relapse [hazard ratio = 7.5, 95% confidence interval (3.0–19.0); P < 0.001]. Tumors that turned F. ...

وصف الملف: application/pdf; image/jpeg

العلاقة: Annals of Oncology;31(10); https://doi.org/10.1016/j.annonc.2020.06.003Test; Serna G, Ruiz-Pace F, Hernando J, Alonso L, Fasani R, Landolfi S, et al. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020 Oct;31(10):1366–75.; https://hdl.handle.net/11351/6378Test; 000574680100001

الإتاحة: https://doi.org/10.1016/j.annonc.2020.06.003Test
https://hdl.handle.net/11351/6378Test

المؤلفون: Carmona-bayonas, Alberto, Jiménez-fonseca, Paula, Lamarca, Ángela, Barriuso, Jorge, Castaño, Ángel, Benavent, Marta, Alonso, Vicente, Riesco-martínez, María Del Carmen, Alonso-gordoa, Teresa, Custodio, Ana, Sánchez Cánovas, Manuel, Hernando Cubero, Jorge, López, Carlos, Lacasta, Adelaida, Fernández Montes, Ana, Marazuela, Mónica, Crespo, Guillermo, Escudero, Pilar, Diaz, José Ángel, Feliciangeli, Eduardo, Gallego, Javier, Llanos, Marta, Segura, Ángel, Vilardell, Felip, Percovich, Juan Carlos, Grande, Enrique, Capdevila, Jaume, Valle, Juan W., García-carbonero, Rocío

المصدر: Carmona-bayonas , A , Jiménez-fonseca , P , Lamarca , Á , Barriuso , J , Castaño , Á , Benavent , M , Alonso , V , Riesco-martínez , M D C , Alonso-gordoa , T , Custodio , A , Sánchez Cánovas , M , Hernando Cubero , J , López , C , Lacasta , A , Fernández Montes , A , Marazuela , M , Crespo , G , Escudero , P , Diaz , J Á , Feliciangeli , E , Gallego , J , Llanos , M , Segura , Á , Vilardell ....

مصطلحات موضوعية: somatostatin analogs, lanreotide, neuroendocrine tumors, nomogram, octreotide, prognostic model, progression-free survival, ResearchInstitutes_Networks_Beacons/mcrc, Manchester Cancer Research Centre

الوصف: PURPOSE Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current study was to develop and validate a progression-free survival (PFS) prediction model in SSA-treated patients. PATIENTS AND METHODS We extracted data from the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE). Patient eligibility criteria included GEP primary, Ki-67 of 20% or less, and first-line SSA monotherapy for advanced disease. An accelerated failure time model was developed to predict PFS, which was represented as a nomogram and an online calculator. The nomogram was externally validated in an independent series of consecutive eligible patients (The Christie NHS Foundation Trust, Manchester, United Kingdom). RESULTS We recruited 535 patients (R-GETNE, n = 438; Manchester, n = 97). Median PFS and overall survival in the derivation cohort were 28.7 (95% CI, 23.8 to 31.1) and 85.9 months (95% CI, 71.5 to 96.7 months), respectively. Nine covariates significantly associated with PFS were primary tumor location, Ki-67 percentage, neutrophil-to-lymphocyte ratio, alkaline phosphatase, extent of liver involvement, presence of bone and peritoneal metastases, documented progression status, and the presence of symptoms when initiating SSA. The GETNE-TRASGU (Treated With Analog of Somatostatin in Gastroenteropancreatic and Unknown Primary NETs) model demonstrated suitable calibration, as well as fair discrimination ability with a C-index value of 0.714 (95% CI, 0.680 to 0.747) and 0.732 (95% CI, 0.658 to 0.806) in the derivation and validation series, respectively. CONCLUSION The GETNE-TRASGU evidence-based prognostic tool stratifies patients with GEP neuroendocrine tumors receiving SSA treatment according to their estimated PFS. This nomogram may be useful when stratifying patients with neuroendocrine tumors in future trials. Furthermore, it could be a ...

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1200/JCO.19.00980Test
https://research.manchester.ac.uk/en/publications/d2d3b527-1f1d-4af6-996b-0761cc39e363Test
https://pure.manchester.ac.uk/ws/files/121181372/jco.19.00980.pdfTest